Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant

被引:40
作者
Ferguson, EA
Eccles, R
机构
[1] Common Cold Centre, University of Wales, Cardiff
[2] Common Cold Centre, Sch. of Molec. and Med. Biosciences, University of Wales, Cardiff, Cardiff CF1 3US
关键词
common cold; nasal decongestant; nitric oxide; nose; oxymetazoline;
D O I
10.3109/00016489709113447
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Nitric oxide (NO) is known to play a role in the non-specific host defence mechanism. Furthermore, it has been proposed that NO may be important in respiratory defence against the viruses which cause the common cold. Indeed, elevated NO levels have previously been observed in orally expired air during upper respiratory tract infection (URTI), We wanted to investigate further the role of NO in the host response to URTI. Total nasal airway resistance (tNAR) and nasal NO levels were obtained during symptomatic URTI in 97 subjects. Of these, 80 received treatment with either oxymetazoline or a placebo spray. Post-treatment tNAR and NO levels were obtained 60 min after treatment. Measurements of NO were also repeated 4-6 weeks later, when subjects were healthy, (n = 82). NO levels were measured using a chemiluminescence gas analyser whilst tNAR was measured using posterior rhinomanometry. The mean pre-treatment NO level (1063 +/- 541 ppb) was shown to be reduced significantly after treatment with oxymetazoline (827 +/- 373 ppb), p < 0.0001. The mean pre-treatment rNAR, 0.42 Pa cm(-3) sec(-1), was also reduced significantly to 0.21 Pa Cm-1 sec(-1) (I) < 0.001) after treatment with oxymetazoline. There was no significant correlation between the change in NO levels and change in tNAR following treatment with oxymetazoline (p, corrected for ties = 0.011, p = 0.98). No significant difference was found between NO levels obtained during URTI (1130 +/- 444 ppb) when compared to values obtained when healthy (1197 +/- 361 ppb), p = 0.25. These results demonstrate that treatment with a topical nasal decongestant spray causes a reduction in nasal NO levels. We propose that this occurs as an indirect consequence of the vasoconstrictor actions of oxymetazoline. Since no change in NO levels was observed during URTI, we propose that the NO synthase responsible for NO production in the nose responds in a different manner to that in the lungs.
引用
收藏
页码:614 / 617
页数:4
相关论文
共 14 条
[1]   VASCULAR EFFECTS OF TOPICAL OXYMETAZOLINE ON HUMAN NASAL-MUCOSA [J].
BENDE, M ;
LOTH, S .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1986, 100 (03) :285-288
[2]   EVIDENCE FOR AN ANTIVIRAL EFFECT OF NITRIC-OXIDE - INHIBITION OF HERPES-SIMPLEX VIRUS TYPE-1 REPLICATION [J].
CROEN, KD .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) :2446-2452
[3]   Expression of nitric oxide synthase human nasal mucosa [J].
Furukawa, K ;
Harrison, DG ;
Saleh, D ;
Shennib, H ;
Chagnon, FP ;
Giaid, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (02) :847-850
[4]  
GIRAUD GD, 1995, FASEB J, V9, pA326
[5]   INHIBITION OF VIRAL REPLICATION BY INTERFERON-GAMMA-INDUCED NITRIC-OXIDE SYNTHASE [J].
KARUPIAH, G ;
XIE, QW ;
BULLER, RML ;
NATHAN, C ;
DUARTE, C ;
MACMICKING, JD .
SCIENCE, 1993, 261 (5127) :1445-1448
[6]   INCREASED NITRIC-OXIDE IN EXHALED AIR OF NORMAL HUMAN-SUBJECTS WITH UPPER RESPIRATORY-TRACT INFECTIONS [J].
KHARITONOV, SA ;
YATES, D ;
BARNES, PJ .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (02) :295-297
[7]  
Lundberg J, 1996, ACTA PHYSIOL SCAND, V157, P1
[8]   PRIMARILY NASAL ORIGIN OF EXHALED NITRIC-OXIDE AND ABSENCE IN KARTAGENERS-SYNDROME [J].
LUNDBERG, JON ;
WEITZBERG, E ;
NORDVALL, SL ;
KUYLENSTIERNA, R ;
LUNDBERG, JM ;
ALVING, K .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (08) :1501-1504
[9]   HIGH NITRIC-OXIDE PRODUCTION IN HUMAN PARANASAL SINUSES [J].
LUNDBERG, JON ;
FARKASSZALLASI, T ;
WEITZBERG, E ;
RINDER, J ;
LIDHOLM, J ;
ANGGARD, A ;
HOKFELT, T ;
LUNDBERG, JM ;
ALVING, K .
NATURE MEDICINE, 1995, 1 (04) :370-373
[10]  
MONCADA S, 1991, PHARMACOL REV, V43, P109